TAC Stock Recent News

Q2 2024 and FY 2024 Key Highlights Q2 Financials - Beat on Revenues, ex-TAC and Adj. EBITDA; Growth rates accelerate Q2 2024 Results: Revenues $428M, Gross profit $115M, ex-TAC Gross Profit $150M, Net loss $4M, Non-GAAP Net Income $23M, Adj.

Patient enrollment has accelerated, now with 13 patients enrolled in trial TFF TAC at ~20% of the oral tacrolimus dose prevented acute rejection and achieved >80% of the previous oral trough blood levels -- leading to diminished drug burden 9 out of 9 (100%) patients who completed the 12-week treatment chose to remain on TFF TAC by proceeding to the long-term extension Phase; 2 patients have been treated for over a year and 6 patients have been treated for more than 6 months Observed a 6.5-fold reduction in the number of abnormally expressed rejection-related gene sets after treatment with TFF TAC No production of donor-specific antibodies (DSA) after treatment with TFF TAC FORT WORTH, Texas, Aug. 06, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today provided an update

TransAlta Corporation (NYSE:TAC ) Q2 2024 Earnings Conference Call August 1, 2024 11:00 AM ET Company Participants Chiara Valentini - VP, Strategic Finance & Investor Relations John Kousinioris - President & CEO Joel Hunter - EVP, Finance & CFO Blain Van Melle - EVP, Commercial & Customer Relations Conference Call Participants Patrick Kenny - National Bank Financial Mark Jarvi - CIBC Capital Markets Maurice Choy - RBC Capital Markets John Mould - TD Cowen Benjamin Pham - BMO Capital Markets Operator Good morning. My name is Amy, and I will be your conference operator today.

CALGARY, Alberta, Aug. 01, 2024 (GLOBE NEWSWIRE) -- TransAlta Corporation (“TransAlta” or the “Company”) (TSX: TA) (NYSE: TAC) today reported its financial results for the three and six months ended June 30, 2024, demonstrating strong financial performance and reaffirming its 2024 outlook.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

CALGARY, Alberta, July 29, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of TransAlta Corporation (TSX: TA) (NYSE: TAC) declared a quarterly dividend of $0.06 per common share payable on October 1, 2024, to shareholders of record at the close of business on September 1, 2024.

TransAlta (TAC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The mean of analysts' price targets for TransAlta (TAC) points to an 86.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

CALGARY, Alberta, July 04, 2024 (GLOBE NEWSWIRE) -- TransAlta will release its second quarter 2024 results before markets open on Thursday, August 1, 2024. A conference call and webcast to discuss the results will be held for investors, analysts, members of the media and other interested parties the same day beginning at 9:00 a.m. Mountain Time (11:00 a.m. ET). The media will be invited to ask questions following analysts.

ROCKAWAY, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is thrilled to announce the Commercial Off the Shelf (COTS) availability of the next generation TAC-STIM™, a non-invasive vagus nerve stimulator (nVNS) designed in partnership with the US military to enhance human performance exclusively for active-duty military use.